Jan E. Berger, MD, MJ

home / authors / jan-e-berger-md-mj

Articles

October 30th 2024

The Need for Regulation to Positively Impact Drug Formulary Decisions to Ensure Appropriate Patient Access: A Little-Discussed Topic in Pharmaceutical Policy and Pricing Debate

Jan E. Berger, MD, MJ

As health care moves toward a value-based payment model, the pharmacy benefit is going in the opposite direction, one that places unit cost over clinical appropriateness.

May 14th 2021

Letter From the Editorial Board: Jan E. Berger, MD, MJ

Jan E. Berger, MD, MJ

July 2nd 2020

Food as Medicine: Impact on Diabetes Management

Jan E. Berger, MD, MJ Denise Giambalvo, MHRM Dawn Weddle, RD

This article addresses what employers need to know about food as medicine and offers practical steps to reduce barriers for their employee populations.

September 13th 2019

From the Editorial Board: Jan E. Berger, MD, MJ

Jan E. Berger, MD, MJ

July 2nd 2013

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

Michael E. Chernew, PhD Rick McKellar, BS Wade Aubry, MD Roy Beck, MD, PhD Joshua Benner, PharmD, ScD Jan E. Berger, MD, MJ A. Mark Fendrick, MD Felicia Forma, BSc Dana Goldman, PhD Anne Peters, MD Rebecca Killion, MA Darius Lakdawalla, PhD Douglas K. Owens, MD Joe Stahl, MA

February 12th 2013

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.

November 2nd 2009

Prescriber Compliance With Black Box Warnings in Older Adult Patients

Judith A. Ricci, ScD, MS Charmaine Coulen, MPH Jan E. Berger, MD, MJ Marsha C. Moore, MD, MBA Angela McQueen, PharmD Saira A. Jan, PharmD

Elderly patients prescribed drugs with a drug-laboratory black box warning (BBW) had lower rates of prescriber BBW compliance than patients prescribed drugs with a drug-disease warning.